Bioglutide

Bioglutide (NA-931) is a first-in-class oral quadruple receptor agonist targeting IGF-1, GLP-1, GIP, and glucagon receptors simultaneously. Developed by Biomed Industries, this small molecule derived from a cyclic IGF-1 fragment demonstrates remarkable oral bioavailability and blood-brain barrier penetration. Phase 2 clinical trials showed up to 13.8% body weight reduction in 13 weeks while preserving muscle mass - a significant advantage over existing GLP-1 therapies. Currently in Phase 2b/3 trials for obesity and type 2 diabetes.

Oral administration (no injections), muscle-sparing weight loss, once-daily dosing with or without food, milder GI side effects than injectable GLP-1s, quadruple receptor activation for comprehensive metabolic effects.

NA-931 is a small lipophilic molecule derived from cyclic IGF-1 fragment that crosses the blood-brain barrier. Simultaneously activates IGF-1 (muscle preservation, insulin sensitivity), GLP-1 (appetite suppression, insulin secretion), GIP (glucose metabolism, fat storage), and glucagon (energy expenditure, fat oxidation) receptors.

Research protocols from published literature — not dosing recommendations.

• Tirzepatide — Being Studied: Active clinical trial (NCT06732245) evaluating NA-931 + Tirzepatide combination for enhanced weight loss
• Semaglutide — Avoid Combination: Both activate GLP-1 receptors - combining creates redundancy and compounded GI side effects risk
• Retatrutide — Avoid Combination: Both are multi-agonists targeting overlapping pathways (GLP-1, GIP, glucagon) - avoid stacking
• CJC-1295 — Compatible: Different mechanisms - CJC-1295 stimulates GH release while Bioglutide targets metabolic receptors. May complement for body composition
• Ipamorelin — Compatible: May help maintain metabolic rate and support muscle preservation during weight loss
• BPC-157 — Compatible: No known interactions - BPC-157 may support gut health during GLP-1 therapy
• 5-Amino-1MQ — Compatible: NNMT inhibition may complement metabolic effects for enhanced fat loss
• MOTS-c — Compatible: Different metabolic pathways - may be synergistic for fat loss and energy metabolism

Week 1-2: Possible mild appetite reduction, minimal GI effects. Week 2-4: Noticeable appetite suppression, early weight loss. Week 4-8: Steady weight loss (1-2+ lbs/week), improved energy. Week 8-13: Continued weight loss, 10-14% total reduction possible. Side effects generally milder than injectable GLP-1 therapies. Muscle mass preservation reported in clinical trials. Metabolic improvements (glucose, lipids) develop over weeks.

Investigational drug - not yet FDA approved. Start at lower dose (50mg) and titrate up as tolerated. Most common side effects: mild nausea (7.3%), diarrhea (6.3-8.1%). 83% of GI adverse events rated mild or insignificant in trials. No serious drug-related adverse events in Phase 2. Caution with personal/family history of medullary thyroid carcinoma (GLP-1 class concern). Monitor for pancreatitis symptoms (severe abdominal pain). Drug interactions not fully characterized - avoid stacking with other GLP-1 agonists.

Investigational drug - not yet FDA approved. Start at lower dose (50mg) and titrate up as tolerated. Most common side effects: mild nausea (7.3%), diarrhea (6.3-8.1%). 83% of GI adverse events rated mild or insignificant in trials. No serious drug-related adverse events in Phase 2. Caution with personal/family history of medullary thyroid carcinoma (GLP-1 class concern). Monitor for pancreatitis symptoms (severe abdominal pain). Drug interactions not fully characterized - avoid stacking with other GLP-1 agonists.

Bioglutide should be stored at Room temperature, protect from moisture.